Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other Operating Expenses for 4 consecutive years, with $2.4 million as the latest value for Q2 2025.

  • Quarterly Other Operating Expenses fell 52.25% to $2.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 84.84% year-over-year, with the annual reading at $2.4 million for FY2025, 84.84% down from the prior year.
  • Other Operating Expenses hit $2.4 million in Q2 2025 for Allogene Therapeutics, down from $10.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $13.2 million in Q4 2023 to a low of $2.4 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged $7.8 million across 3 years, with a median of $7.9 million in 2024.
  • Biggest YoY gain for Other Operating Expenses was 52.25% in 2025; the steepest drop was 52.25% in 2025.
  • Year by year, Other Operating Expenses stood at $13.2 million in 2023, then decreased by 19.0% to $10.7 million in 2024, then tumbled by 77.8% to $2.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for ALLO at $2.4 million in Q2 2025, $10.7 million in Q3 2024, and $5.0 million in Q2 2024.